Depomed (NASDAQ: DEPO) reported Q3 EPS of $0.33, $0.14 better than the analyst estimate of $0.19. Revenue for the quarter came in at $105 million versus the consensus estimate of $101.64 million.

Opportunities for Sustained Growth·

• NUCYNTA is strongly positioned for future growth
  • Depomed's first full quarter promoting NUCYNTA complete with its experienced pain and neurology sales force, over three times more than previous promotional effort
  • Successful deployment of marketing and medical programs supporting NUCYNTA
  • Positive physician feedback indicative of traction gaining in chronic lower back pain market
  • Education on dosing and titration has potential for improved patient experience
  • Diabetic peripheral neuropathy market represents a largely untapped opportunity
• Continued strong formulary coverage expected in 2016 for our portfolio providing broad patient access to Depomed products
• Lengthy market exclusivity expected for NUCYNTA beyond 2023 and potentially to 2028, with rest of portfolio maintaining at least 6 years and up to 9 years exclusivity
• Potential future cash flow from IP litigation against Purdue and Endo
• Exceptional cash generation supports our "Acquire-Integrate-Grow" strategy

For earnings history and earnings-related data on Depomed (DEPO) click here.